secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2023-10-25T23:59:59+00:00
Accession:  0001493152-23-038297
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaPro subsidiary files financials; spinout of cancer assets completed Aug 31, 2023
--------------------------------------------------------------------------------

- BriaPro filed Jul 31, 2023 financials: $1 cash, zero revenue, inactive during period.
- On Aug 31, 2023, BriaPro closed spinout of Bria-TILsRx and PKCδ inhibitors from parent BriaCell.
- Spinout consideration: 47,945,178 BriaPro shares issued; BriaCell owns ~31,963,452 (2/3).
- BriaCell options/warrants adjusted; 2,131,400 options and 8,121,650 warrants outstanding with split exercise prices.
- BriaPro notes going concern uncertainty; will need additional financing to develop assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223038297/0001493152-23-038297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000149315223038297/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-038297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer